肝癌射频消融术后联合替吉奥节拍化疗的疗效评价

doi:10.11904/j.issn.1002-3070.2016.01.004

实用肿瘤学杂志 ›› 2016, Vol. 30 ›› Issue (1): 17-22.doi: 10.11904/j.issn.1002-3070.2016.01.004

肝癌射频消融术后联合替吉奥节拍化疗的疗效评价

康振国, 纪卫政, 顾俊鹏, 朱帝文, 张海潇, 任伟新

新疆医科大学第一附属医院介入放射科(乌鲁木齐 830054)

收稿日期:2015-07-04 出版日期:2016-02-28 发布日期:2016-02-25
通讯作者: 任伟新,E-mail:cjr.renweixin@vip.163.com
作者简介:康振国,男,(1983-),硕士研究生,从事介入放射的研究

The therapeutic evaluation of radiofrequency ablation combined with S-1 capsules metronomic chemotherapy for hepatocellular carcinoma

KANG Zhenguo, JI Weizheng, GU Junpeng, ZHU Diwen, ZHANG Haixiao, REN Weixin

Department of Interventional Radiology,First Affiliated Hospital,Sinkiang Medical University,Urumqi 830054,China

Received:2015-07-04 Online:2016-02-28 Published:2016-02-25

摘要/Abstract

摘要： 目的探讨肝癌患者射频消融术后口服低剂量替吉奥的节拍化疗临床疗效。方法选择接受射频消融术的肝癌患者,按照术后是否口服替吉奥进行节拍化疗分为RFA+替吉奥组和RFA对照组,回顾性分析两组患者术后18个月内的临床疗效,评价其原发肿瘤控制率和无疾病进展时间。结果随访观察显示,术后9个月RFA+替吉奥组的肿瘤控制率为93.3%,RFA对照组肿瘤控制率为73.4%,差异有统计学意义(P=0.038);随访18个月内,RFA+替吉奥组无疾病进展时间中位数为16.25个月,RFA对照组无疾病进展时间中位数降低为12.25个月(P＜0.001);1年无疾病进展率在RFA对照组为53.3%,显著低于RFA+替吉奥组83.3%(P=0.012)。两组均无治疗相关性死亡,主要并发症发生率为13.3%。结论射频消融术后进行替吉奥节拍化疗治疗肝癌可以减缓肿瘤进展,延长肝癌患者的无疾病进展时间。

关键词: 肝癌, 射频消融术, 替吉奥, 节拍化疗, 疗效评价

Abstract: Objective To explore the clinical efficiency and safety of radiofrequency ablation combined with Tegafur,Gimeracil and Oteracil Porassium Capsules(S-1 capsules)for hepatocellular carcinoma.Methods Sixty HCC patients included in this study were underwent initial radiofrequency ablation and then they were divided into RFA+S-1 group and RFA control group according to the metronomic chemotherapy either with S-1 or not.The local tumor control and disease free survival outcome between the two groups were compared.Results Follow-up observation showed that the total control rate after 9 months′ treatment was 93.3% in RFA+S-1 group vs.73.4% in RFA control group(P=0.038).During the 18 months of follow up,the median time for disease free survival was 16.25 months in RFA+S-1 group vs.12.25 months in RFA control group(P＜0.001).One-year progression free survival rate in RFA group was 53.3%,which was significantly lower than the RFA + S-1 group(83.3%)(P=0.012).The major complication rate was 13.3%.No procedu rerelated death or severe complications occurred.Conclusion Metronomic chemotherapy with S-1 following initial radiofrequency ablation delays tumor progression and prolongs overall survival of patients with HCC tumors.

Key words: Hepatocellular carcinoma, Radiofrequency ablation, S-1, Metronomic chemotherapy, Therapeutic evaluation

中图分类号:

R735.7

康振国, 纪卫政, 顾俊鹏, 朱帝文, 张海潇, 任伟新. 肝癌射频消融术后联合替吉奥节拍化疗的疗效评价[J]. 实用肿瘤学杂志, 2016, 30(1): 17-22.

KANG Zhenguo, JI Weizheng, GU Junpeng, ZHU Diwen, ZHANG Haixiao, REN Weixin. The therapeutic evaluation of radiofrequency ablation combined with S-1 capsules metronomic chemotherapy for hepatocellular carcinoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 17-22.

参考文献

1 Marin-Hargreaves G,Azoulay D,Bismuth H.Hepatocellular carcinoma:surgical indications and results[J].Crit Rev Oncol Hematol,2003,(47):13-27.
2 管清龙,任伟新,纪卫政,等.射频消融治疗肝癌后血清内VEGF的变化与预后的相关性分析[J].现代诊断与治疗,2013,(9):1955-1956.
3 管清龙,任伟新,纪卫政,等.肝癌治疗后血清内血管内皮生长因子对预后影响的研究进展[J].介入放射学杂志,2013,22(8):701-704.
4 Miller KD,Sweeney CJ,Sledge GW.Redefining the target:chemotherapeutics as antiangiogenics[J].Clin Oncol,2001,19(4):1195-1206.
5 Qin S,Bai Y,Lim HY,et al.Randomized,multicenter,open-label study of oxaliplatin plus fluorouracil/leucovorin versus Doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].Journal of Clinical Oncology,2013,31(28):3501-3508.
6 Racz GB,Ruiz-Lopez R.Radiofrequency procedures[J].Pain Pract,2006,6(1):46-50.
7 Lencioni R,Crocetti L.Radiofrequency ablation of liver cancer[J].Tech Vasc Interv Radiol,2007,10(1):38-46.
8 Valls C,Ruiz S,Barrau V,et al.Radiofrequency ablation of hepatic tumors[J].Radiology,2006,48(2):53-69.
9 Machi J,Uchida S,Sumida K,et al.Ultrasound-guided radiofrequency thermal ablation of liver tumors:percutaneous,laparoscopic,and open surgical approaches[J].J Gastrointest Surg,2001,10(5):477-489.
10 Ho DH,Pardur R,Couington WP,et al.Comparison of 5-fluorocuracil pharmacokinetics in patients receiving continuous 5-fluorocuracd infusion and oral uracil plus N1-(2′-tetrahydrofuryh)-5-fluorocuracil[J].Clin Cancer Res,1998,4(1):2085-2088.
11 石建华,刘硕新,朱志真,等.替加氟持续低剂量口服治疗晚期非小细胞肺癌的临床观察[J].临床肿瘤学杂志,2008,13(9):800-802.
12 Wu FL,Lu DC,Ying YP,et al.A Meta-analysis reveals S-1-based chemotherapy improves the survival of patients with advanced gastric cancer[J].Medicine(Baltimore),2015,94(16):e652.
13 Matsuda C,Uemura M,Nakata K,et al.Randomized phase II study of S-1 dosing schedule for resected colorectal cancer[J].BMC Cancer,2015,15(1):452.
14 Chang H,Shin SK,Cho BC,et al.A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer[J].Cancer Chemother Pharmacol,2014,73(4):665-71.
15 Tetsuji T,Shunsuke K,Hiroko H,et al.Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment:a phase I trial[J].BMC Cancer,2014,14:301.
16 Hui MY,Wei Z,Xi A,et al.Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma conforming to the Milan criteria:systemic review and meta-analysis[J].Int J Clin Exp Med,2014,7(10):3150-3163.
17 Iwamoto H,Torimura T,Nakamura T,et al.Metronomic S-1 chemotherapy and vandetanib,an efficacious and nontoxic treatment for hepatocellular carcinoma[J].Neoplasia,2011,13(3):187-197.
18 Ghiringheiii F,Menard C,Puig PE,et al.Metronomic cyciophosphamide regime selectively depletes CD4⁺ CD25⁺ regulatory T cells and restores T and NK effector functions in end stage cancer patients[J].Cancer Immunol Immunother,2007,56(5):641-648.

[1]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[2]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[3]	徐兵, 黄素钦, 吴林岚, 魏建威, 杨晓梅, 赵芝萍, 陈怡, 蒋晓织. 异体淋巴细胞和自体淋巴细胞序贯局部注射对小鼠肝癌移植瘤的治疗作用[J]. 实用肿瘤学杂志, 2018, 32(6): 493-497.
[4]	贺伟, 母齐鸣, 王刚, 万波, 廖波, 杨娟. TACC3和p53蛋白在原发性肝癌组织中的表达及其临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 420-425.
[5]	石小康(综述), 丁佑铭(审校). 螺杆菌属与原发性肝癌关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(3): 271-274.
[6]	翟可可, 高媛媛, 冯晓, 许静文, 宫玉芳, 孟庆威. 术后辅助化疗后复发转移与初次诊断的IV期NSCLC一线化疗疗效分析[J]. 实用肿瘤学杂志, 2018, 32(2): 107-111.
[7]	文娟娟, 瞿兵, 刘超. 肝癌组织中抗凝血酶Ⅲ基因表达的临床意义[J]. 实用肿瘤学杂志, 2018, 32(2): 117-121.
[8]	王睿,余陈欢,方杰. miR-409-5p对肝癌细胞系HepG2增殖及迁移的影响[J]. 实用肿瘤学杂志, 2017, 31(4): 305-309.
[9]	石峰,于雁. 节拍化疗通过影响血管形成及免疫系统抑制肿瘤细胞生长的机制[J]. 实用肿瘤学杂志, 2017, 31(4): 316-320.
[10]	周春芳，赵珊珊，孙泽群，吴军，查火龙，袁雅红. 酸性环境诱导肝癌HepG2细胞EMT[J]. 实用肿瘤学杂志, 2017, 31(3): 199-204.
[11]	张丽霞，潘双花，何英平. 原发性肝癌患者心电图与转氨酶和电解质的相关性研究[J]. 实用肿瘤学杂志, 2016, 30(6): 523-526.
[12]	杨晓文, 于爱清, 杨毅. Nanog调控细胞周期相关蛋白影响HepG2细胞增殖能力[J]. 实用肿瘤学杂志, 2016, 30(5): 425-429.
[13]	赵相轩, 温锋, 毛晓楠综述, 卢再鸣审校. 细胞凋亡在原发性肝癌治疗中的作用研究进展[J]. 实用肿瘤学杂志, 2016, 30(5): 448-452.
[14]	余庆, 张文美, 孙迎迎, 龚媛媛, 李东升, 王小莉. TRIM5α对肝癌细胞增殖和凋亡的影响[J]. 实用肿瘤学杂志, 2016, 30(2): 103-108.
[15]	李凯, 杨光, 沈海洋, 刘家. 巨块型肝癌患者首次TACE后发热的临床意义及影响因素[J]. 实用肿瘤学杂志, 2015, 29(6): 528-532.

肝癌射频消融术后联合替吉奥节拍化疗的疗效评价

The therapeutic evaluation of radiofrequency ablation combined with S-1 capsules metronomic chemotherapy for hepatocellular carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价